Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Tucson, ArizonaAges 18 years+ - NCT05823285RecruitingPhase 1
Study of QLS31903 for advanced solid tumors
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06225856RecruitingPhase 1
YY201 for advanced solid tumors and blood cancers
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT07803965RecruitingPhase 2
Study of an injection for severe acute pancreatitis
This trial tests an investigational medicine called SGC001 given as an injection to people with severe acute pancreatitis, a serious inflammation of the pancreas. The study aims to see if the drug is safe and helpful, and to gather early information on how it works.
ChengduAges 18–75 - NCT06519552RecruitingPhase 1
Gene therapy study for adults with MPS type I
This study tests a new gene therapy called JWK008 for adults with MPS type I. The goal is to see if it is safe and can help improve symptoms. You may be able to join if you are 18 or older and have not had serious side effects from enzyme replacement therapy.
Chengdu, SichuanAges 18 years+ - NCT07767630RecruitingEarly Phase 1
Targeted radiation therapy for relapsed neuroblastoma
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
Chengdu, SichuanAges 1–100 - NCT07735377RecruitingPhase 1
Study of SHR-6914 for Prostate Cancer
This study tests a new drug called SHR-6914 in men with prostate cancer that has spread. The goal is to see if it is safe and helps shrink or control the cancer, and to learn how the body processes it.
Guangzhou, GuangdongAges 18–80 - NCT05200650RecruitingPhase 1
Test gel with cisplatin injected into head and neck tumors
This trial studies an anti-cancer gel that delivers cisplatin directly into a head and neck tumor with a single injection. It mainly checks safety and side effects, and also looks for early signs that the tumor responds in people whose cancer is progressing or no longer responds to standard treatment.
JerusalemAges 18–80 - NCT06390774RecruitingPhase 1
Study of SSGJ-705 for advanced cancers
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT07682896RecruitingPhase 2
Testing YB-101 for safety and effectiveness in Graves' disease
This trial tests an investigational drug called YB-101 for people with Graves' disease, whether or not they have thyroid eye disease. The goal is to see if the drug is safe and can help.
Gilbert, ArizonaAges 18 years+ - NCT07668518RecruitingPhase 1/Phase 2
Study of KIT2014 for moderate to severe COPD
This trial tests a new medicine called KIT2014 in people with moderate to severe COPD. It aims to see if the drug is safe, tolerable, and helps improve breathing and COPD symptoms.
Charlestown, New South WalesAges 40–80 - NCT06608355RecruitingPhase 1
Stem cell treatment for early-onset Parkinson's
This trial tests a new stem cell treatment called NouvNeu001 for people with early-onset Parkinson's disease. The goal is to see if it's safe and if it can help improve movement and daily life.
Wuhan, HubeiAges 18–70 - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT07554495RecruitingPhase 3
Filgotinib for moderate to severe polyarticular juvenile arthritis
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
LeuvenAges 8–18 - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07538128RecruitingEarly Phase 1
New drug YSCH-01 with immunotherapy for recurrent brain cancer
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07498725RecruitingPhase 1/Phase 2
Study of LRK-4189 for solid tumors that have spread or can't be removed
This trial tests a new drug called LRK-4189, alone or with other treatments, for people with advanced solid tumors that have worsened despite prior therapy. The goal is to see if it is safe, tolerable, and helpful against the cancer.
NiceAges 18 years+ - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07490951Recruiting
CAR-T cell therapy for refractory autoimmune diseases
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
Wuhan, HubeiAges 18–70 - NCT06600022RecruitingPhase 1/Phase 2
Studying SCTB41 for advanced solid tumors
This trial tests a new drug called SCTB41 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it shrinks tumors.
Guangzhou, GuangdongAges 18 years+ - NCT07459166RecruitingPhase 2
Testing a new drug for fentanyl overdose
This study tests a new drug, CS-1103, to see if it can safely help reverse the effects of fentanyl (a strong opioid) even after a naloxone block. Healthy volunteers who have used opioids before will be given fentanyl and then the study drug, while researchers monitor safety and how the drug works.
Glendale, CaliforniaAges 18–55
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.